by Gemma Escarré,
This round is bridge funding towards a round to raise between €3 million and €5 million in venture capital to complete phase II clinical trials on the drug ABTL0812 for lung and endometrial cancer in Spain and France.
ABTL0812 is administered in combination with chemotherapy as a first-line therapy and maintenance therapy.
Both Ability Pharma and Capital Cell are members of CataloniaBio & HealthTech.
Photo: Carles Domènech, CEO of Ability Pharma